Pharmanutra PR Stock: price and insider trades · Italy
Pharmanutra PR: what insiders have been doing
We have very little insider data for Pharmanutra PR so far: the most recent filing dates from 16 April 2025. With so few records, no pattern can be drawn yet. These figures are compiled from regulatory filings published by Consob. They describe what insiders did and are not a recommendation.
Insider Decl.
6
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 7,995 of 26,897 companies
61.7
score / 100
Value38
Quality85
FCF yld2.1%
Earn yld2.6%
EV/EBITDA23.5x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€81.90
Analyst consensus
3 analysts1.00/5
€76.00Target €81.33(-1%)€86.00
Income statement
Revenue€132.9M
Gross profit€102.9M77% margin
EBITDA€34.3M26% margin
Net income€20.0M15.1% margin
Valuation
PER (trailing)37.2x
PER (forward)26.7x
P/Book10.6x
Beta0.17
Balance sheet & cash
Market cap€784.2M
Total debt€20.5M
Free Cash Flow€16.4M
Debt / Equity26%
Profitability & ownership
ROE30.1%
ROA15.2%
% insiders65.0%
% institutions17.2%
Last declaration on 16 April 2025
Declarations6 total
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
- ●Executives0Consob
6 of 6 declarations
About Pharmanutra PR
Pharmanutra PR is a company specialized in the health and pharmaceutical sector, listed on the XMIL market. It focuses on the development and commercialization of innovative nutraceutical and pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
